公司資料
Mesoblast 股價、新聞與催化劑
- 股票代碼:
- MESO
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- Australia and listed in the U
股票表現
14.87 USD (+3.19%)
收盤價
最後更新: 2026年9月17日
1.88B USD
市值
股價為何變動
截至 2026年9月17日，MESO 上漲 3.19%，收於 $14.87。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
業務概覽
Mesoblast is a regenerative medicine company focused on cell-based therapies for inflammatory and degenerative diseases. Its platform has long centered on developing allogeneic cell therapies with broad medical use.
所在地與產業分類
Headquartered in Australia and listed in the U.S. as an ADR, Mesoblast sits in cell therapy and regenerative medicine.
商業模式特徵
The company depends on clinical validation, manufacturing execution, and the ability to commercialize cell-based medicine.
生技產業定位
Mesoblast is a long-running regenerative-medicine name whose valuation depends on clinical and commercial milestones.
未來催化劑
- Mesoblast's catalysts are Ryoncil commercialization and any broader cell-therapy expansion. The stock will care about whether the commercial base keeps building.
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。